IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that its AI-enabled Clinical Decision Support Tool, developed in collaboration with Breakthrough T1D, has won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year. Powered by IQVIA Healthcare-grade AI®, the tool tackles a long-standing proble.

Business Wire • Aug 20, 2026

IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced that it has been ranked No. 1 in Everest Group's “Top 50™ Pharmaceutical Technology Providers” report for 2026. IQVIA earned the highest overall score among the 50 providers evaluated, receiving 96.8 out of 100. The ranking recognizes IQVIA's broad technology cover.

Business Wire • Aug 17, 2026

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

IQVIA shares jump 41.5% in three months as record R&DS bookings, a solid backlog, raised 2026 guidance and share buybacks support sentiment.

Zacks Investment Research • Aug 12, 2026

Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 10, 2026

IQVIA Holdings (IQV) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Aug 7, 2026

Why IQVIA Stock Jumped 13% in a Week and Whether the Gains Can Last

IQV shares jump after Q2 earnings beat, record bookings and higher 2026 guidance, but future gains hinge on execution and backlog conversion.

Zacks Investment Research • Aug 4, 2026

Is IQVIA Stock a Buy as Growth Improves but High Leverage Persists?

IQV's proprietary data platform and expanding clinical research business support growth, but high debt and liquidity risks keep the investment outlook balanced.

Zacks Investment Research • Aug 4, 2026

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

RESEARCH TRIANGLE PARK, N.C. & BOSTON--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery plat.

Business Wire • Aug 4, 2026

An IQVIA CEO Sold $26.1 Million as Bookings Hit a Record $3.15 Billion

The CEO of IQVIA executed an exercise-and-sell of stock appreciation rights involving shares at a weighted average price of $245.51 on July 29, 2026. Bousbib maintains substantial equity exposure through roughly 836,000 directly held shares and about 543,000 shares held indirectly via the Orohena Trust.

The Motley Fool • Aug 2, 2026

An IQVIA Insider Just Sold Over $1 Million in Stock. Here's What Long-Term Investors Should Know

The transaction involved the sale of 5,000 shares at $249.16 per share, representing a total value of about $1.2 million. This disposition resulted in a 19% reduction of the insider total direct equity holdings in the company.

The Motley Fool • Aug 2, 2026